{"analyses":[{"ciLowerLimit":"10.89","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"22.26","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Ratio of adjusted geometric mean","paramValue":"15.57"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"49","value":"3110"},{"groupId":"OG001","spread":"35","value":"509.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Area under the plasma concentration versus time curve from time 0 to end of dosing interval (AUCtau).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days).","id":"OG000","title":"RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg Alone"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) form Cycle 1Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after a meal.","id":"OG001","title":"RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg With Rifampin"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK parameter population was defined as all participants in the Rifampin interaction cohort safety population who satisfied following criteria for Cycle 1 Day 15 or Cycle 2 Day 1: a) had at least 1 of the primary PK parameters of Crizotinib (AUCtau and Cmax). b) received adequate dosing prior to PK sampling. Here, \"Overall number of participants analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"pre-dose, 2, 4, 6, 8 and 10 hours on Cycle 1 Day 15 (Crizotinib alone arm) and Cycle 2 Day 1 (Crizotinib with Rifampin arm)","title":"Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib Alone and When Taken With Rifampin","type":"PRIMARY","unitOfMeasure":"nanogram*hour per milliliter"}